2.47
0.30 (13.82%)
| Previous Close | 2.17 |
| Open | 2.16 |
| Volume | 3,059,208 |
| Avg. Volume (3M) | 3,037,262 |
| Market Cap | 109,716,232 |
| Price / Sales | 38.05 |
| 52 Weeks Range | |
| Earnings Date | 26 Dec 2025 |
| Diluted EPS (TTM) | 4.09 |
| Current Ratio (MRQ) | 0.720 |
| Operating Cash Flow (TTM) | -64.05 M |
| Levered Free Cash Flow (TTM) | -35.91 M |
| Return on Assets (TTM) | -122.34% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Outlook Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -0.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.75 |
|
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 38.31% |
| % Held by Institutions | 16.89% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Lvw Advisors, Llc | 30 Sep 2025 | 48,235 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 8.00 (Ascendiant Capital, 223.89%) | Buy |
| Median | 4.50 (82.19%) | |
| Low | 1.00 (HC Wainwright & Co., -59.51%) | Hold |
| Average | 4.50 (82.19%) | |
| Total | 1 Buy, 1 Hold | |
| Avg. Price @ Call | 1.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 30 Sep 2025 | 1.00 (-59.51%) | Hold | 1.06 |
| Ascendiant Capital | 22 Sep 2025 | 8.00 (223.89%) | Buy | 0.968 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 19 Dec 2025 | Announcement | Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 |
| 24 Nov 2025 | Announcement | Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference |
| 13 Nov 2025 | Announcement | Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD |
| 03 Nov 2025 | Announcement | Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010 |
| 29 Sep 2025 | Announcement | Outlook Therapeutics Provides Update on Type A Meeting with FDA |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |